Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Fresenius Medical Care Q1 2026 Earnings Call - Accelerated Buyback and TDAPA Cliff Loom
Fresenius Medical Care delivered a solid Q1 2026 with 4% organic revenue growth and 10% operating income expansion, driven by the TDAPA tailwind and the FME25+ cost program. The company accelerated it...
- Organic revenue grew 4% in Q1 2026, with operating income up 10%, reflecting strong margin expansion to 10.1%.
- The company completed its EUR 1 billion share buyback in under a year, repurchasing 24.8 million shares (8.5% of capital) and maintaining a 2.6x net leverage ratio.
- TDAPA regulations provided an EUR 80 million tailwind in Q1, but a significant headwind is expected in H2 2026, creating a clear earnings cliff.
- +9 more takeaways
First Watch Restaurant Group Q1 2026 Earnings Call - Digital Marketing ROI and Menu Innovation Drive Profitable Growth
First Watch Restaurant Group delivered a strong first quarter for fiscal 2026, with same-store sales growth of 2.8% and a restaurant-level operating profit margin of 18.5%. The company successfully ro...
- First Watch reported Q1 2026 same-store sales growth of 2.8%, driven by a positive mix shift from its new core menu and seasonal offerings, despite a 2% decline in traffic that was partially weather-related.
- Restaurant-level operating profit margin expanded 200 basis points to 18.5%, supported by carried pricing, commodity deflation on eggs and avocados, and a 90 basis point improvement in labor costs.
- The company accelerated its digital marketing campaign to 75% of the restaurant base, up from one-third in 2025, and is already seeing positive ROI, prompting a pull-forward of several million in marketing spend into Q2.
- +7 more takeaways
Enpro Industries Q1 2026 Earnings Call - Accelerating Semiconductor Demand Drives Raised Guidance
Enpro Industries kicked off 2026 with force, posting 11% sales growth and 13% adjusted EBITDA growth, fueled by a steepening demand curve in its Advanced Surface Technologies (AST) segment and seamles...
- Total company sales rose nearly 11% year-over-year to $303 million, with AST sales up over 11% and Sealing Technologies up 10.8%.
- Adjusted EBITDA increased nearly 13% to $76.4 million, with the total company adjusted EBITDA margin expanding 40 basis points year-over-year to 25.2%.
- Management raised full-year 2026 guidance, now expecting total sales growth of 10%-14% and adjusted EBITDA of $315 million to $330 million.
- +7 more takeaways
FTC Solar Q1 2026 Earnings Call - New CEO Anthony Carroll Takes the Helm as Backlog Surges and Bookings Accelerate
FTC Solar reported a rougher first quarter on paper, with revenue of $17.3 million missing its target range due to a single delayed project. But the real story is the commercial momentum building behi...
- FTC Solar appointed Anthony Carroll as President and CEO, succeeding Yann Brandt. Carroll brings a track record of scaling operations at billion-dollar energy and construction firms, signaling a strategic shift toward aggressive growth and global expansion.
- Q1 revenue came in at $17.3 million, missing the company's guidance range due to a single delayed project expected to contribute $3 to $4 million. However, operating expenses came in better than expected, providing some offset.
- The company secured a major 1-gigawatt Safe Harbor project award for a private equity-backed portfolio company with high-profile off-takers. The first tranche is contracted, and the project is expected to add triple-digit millions to revenue in the back half of 2026 and into 2027.
- +7 more takeaways
Rhythm Pharmaceuticals Q1 2026 Earnings Call - Acquired HO Launch Accelerates with 150+ Start Forms in Six Weeks
Rhythm Pharmaceuticals delivered a strong Q1 2026, driven by steady growth in its ultra-rare Bardet-Biedl syndrome (BBS) base business and the rapid commercial launch of IMCIVREE for acquired hypothal...
- U.S. net revenues reached $60.1 million in Q1 2026, up 5% sequentially, with $36.9 million from the U.S. and $23.2 million internationally.
- IMCIVREE for acquired hypothalamic obesity (HO) launched in the U.S. on March 19, capturing 150+ start forms in six weeks, with ~40 from clinical trial conversions and 80% from new prescribers.
- HO launch pace outpaces Bardet-Biedl syndrome (BBS); early payer approval rates improved due to prior BBS-based education, though specific HO policies expected in 3–9 months.
- +12 more takeaways
Embecta Corp Q2 FY2026 Earnings Call - U.S. Pen Needle Share Loss Drives Guidance Cut and Owen Mumford Acquisition
Embecta delivered a disappointing second quarter of fiscal 2026, with consolidated revenues falling 14.4% year-over-year as U.S. pen needle sales collapsed under competitive share loss and broader mar...
- U.S. Revenue Collapse: U.S. revenue fell 29.4% year-over-year, driven primarily by competitive share loss at a single major customer and broader market softness in insulin pen prescriptions.
- Guidance Cut: Full-year FY2026 revenue guidance is lowered to $1.015 billion–$1.035 billion, reflecting a ~$75 million reduction in organic revenue expectations compared to prior low-end guidance.
- Pen Needle Headwinds: Pen needles, which make up ~70% of the guidance reduction, suffered from ~$25 million in share loss and ~$20 million in market volume softness, exacerbated by patients shifting to lower-cost channels.
- +7 more takeaways
DuPont Q1 2026 Earnings Call - Strong Q1 Results and Raised Full-Year Guidance Driven by Healthcare, Aerospace, and Productivity Gains
DuPont delivered a strong start to 2026, beating guidance with 2% organic sales growth, 130 basis points of pro forma margin expansion, and double-digit adjusted EPS growth. The company closed the $1....
- DuPont reported Q1 2026 net sales of $1.7 billion, up 4% year-over-year, driven by 2% organic growth and a 2% currency benefit. Results exceeded prior guidance.
- Operating EBITDA surged 15% to $414 million, with pro forma margins expanding 130 basis points to 24.6%, reflecting strong operational execution and favorable mix.
- Adjusted EPS reached $0.55 on a reported basis (up 53% YoY) and $0.55 on a pro forma basis (up 20% YoY), beating consensus expectations.
- +9 more takeaways
JELD-WEN Q1 2026 Earnings Call - Service Improvements Offset Volume Declines, Raised Revenue Guidance
JELD-WEN Holdings reported a challenging first quarter, with net revenue falling 7% year-over-year to $722 million and adjusted EBITDA collapsing 72% to $6 million. The decline was driven by a steep d...
- Revenue fell 7% year-over-year to $722 million, driven by a 10% core revenue decline as lower volumes overwhelmed slight pricing gains.
- Adjusted EBITDA collapsed 72% to just $6 million, with a 0.9% margin, as $22 million in volume headwinds and $21 million in price-cost inflation offset $22 million in productivity gains.
- Management raised full-year 2026 revenue guidance to $3.05-$3.2 billion, up from $2.95-$3.1 billion, citing improved service levels and better-than-expected April sales.
- +7 more takeaways
Eve Holding Q1 2026 Earnings Call - Engineering Prototype Flight Tests Validate Path to 2028 Certification
Eve Holding delivered a strong operational quarter, logging 59 flights and validating 130 performance points with its engineering prototype. The company is on track to begin transition flights in the ...
- Eve completed 59 flights and logged nearly two and a half hours in the air with its engineering prototype, validating 130 distinct performance points and reaching 215 feet in altitude and 30 knots forward speed.
- The company is preparing to initiate transition flights in the second quarter, moving from hover mode to partial transition and eventually full wing-borne flight above 85 knots.
- Eve remains on track for certification prototype first flights in the second half of 2027 and a targeted entry to service in 2028, contingent on a 12-month certification flight test campaign.
- +7 more takeaways
Shoals Technologies Group Q1 2026 Earnings Call - Record Backlog and Raised Guidance Signal Solar Demand Resilience
Shoals Technologies Group reported a strong start to 2026, with Q1 revenue of $140.6 million, up 75% year-over-year, driven by robust demand in the U.S. utility-scale solar market. The company achieve...
- Revenue surged 75% year-over-year to $140.6 million, beating guidance and reflecting strong demand in the U.S. utility-scale solar market.
- Record backlog and awarded orders (BLAO) reached $758 million, up 18% year-over-year, with $628 million scheduled for delivery through Q1 2027.
- Adjusted EBITDA grew 56% year-over-year to $21.1 million, landing at the high end of guidance and signaling strong operating leverage.
- +7 more takeaways